Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | NMS-P088 |
Synonyms | |
Therapy Description |
NMS-P088 inhibits Flt3, Kit, and Csf1r, thus may have anti-tumor activity in hematological cancers (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NMS-P088 | NMS 03592088|NMS-03592088|NMS03592088|NMS P088|NMSP088 | CSF1R Inhibitor 26 FLT3 Inhibitor 57 KIT Inhibitor 52 | NMS-P088 inhibits FLT3, KIT, and CSF1R, thus may have anti-tumor activity in hematological cancers (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03922100 | Phase Ib/II | NMS-P088 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Recruiting | ITA | 0 |